Companies › Edesa Biotech
1 active drug program in 1 registered trial: 1 Phase 2; Immunology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| EB06 CXCL10 monoclonal antibody | CXCL10 | Phase 2 | Non-Segmental Vitiligo (NSV) | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07889492 | EB06 | Phase 2 | Non-Segmental Vitiligo (NSV) | Immunology | Dec 2027 |
Cash of $10m on 2026-06-30; operating cash outflow about $10m a year; runway about 13 months at that burn, to Jul 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Abeona Therapeutics Cabaletta Bio Aravax VivaTech International AltruBio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.